Overview of Type 2 Diabetes Mellitus - Heat Map and Analysis
Global prevalence of the disease has risen rapidly in the past several decades, primarily as a result of rising obesity, a major risk factor for T2DM. This has resulted in a large, diverse and rapidly growing market landscape, comprising numerous different drug classes.
12207(firmenpresse) - Albany, New York, January 16, 2017: The latest report focusing on the Pharmaceutical Market has been recently added to the online database of Market Research Hub’s repository. The report covers the present scenario and the growth prospects of the Health Market. It is entitled as “Type 2 Diabetes Mellitus - Heat Map and Analysis”.
Request for Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=915801
Type 2 diabetes mellitus (T2DM) is a chronic, progressive and serious metabolic disorder characterized by hyperglycemia (high blood glucose levels) and associated with numerous complications and co-morbidities, including cardiovascular disease, nephropathy (kidney damage), neuropathy (nerve damage) and retinopathy (retinal damage).
Global prevalence of the disease has risen rapidly in the past several decades, primarily as a result of rising obesity, a major risk factor for T2DM. This has resulted in a large, diverse and rapidly growing market landscape, comprising numerous different drug classes.
Make an Enquiry: http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=915801
In particular, the emergence over the past decade of glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors and sodium-glucose linked transporter-2 (SGLT-2) inhibitors has intensified competition. These new drug classes have been highly commercially successful, leading to considerable market growth. With a highly active late-stage pipeline, this trend is expected to continue over the coming years.
Differences between these products must be understood fully by companies seeking to position a novel drug in this market. This tabular heat map framework, designed to provide an easily digestible summary of these clinical characteristics, provides detailed readouts of all major late-stage clinical trial results for products in the T2DM market and late-stage pipeline. These are split along lines of therapy, and so are reflective of the treatment algorithm used in the clinic.
All safety and efficacy endpoints reported in these trials are displayed, for both the drug and control groups. In addition, key study characteristics such as the size, composition and patient segment of the study population are provided. These results are presented in a visually accessible, color-coded manner in order to maximize ease of use.
The accompanying text provides a detailed analysis of the clinical benchmarks set by the current market landscape, and the anticipated changes to these benchmarks, and to the treatment algorithm, as a result of the late-stage pipeline.
Browse Full Info with TOC: http://www.marketresearchhub.com/report/type-2-diabetes-mellitus-heat-map-and-analysis-report.html
Scope
What are the clinical characteristics of currently approved therapies for T2DM, in terms of specific safety and efficacy parameters?
Will metformin continue to be the preferred first-line therapy?
How will established drug classes such as the GLP-1 receptor agonists be impacted by upcoming pipeline competitors?
Will biosimilar erosion significantly impact the insulin market?
What technologies are late-stage pipeline therapies employing to improve patient convenience and ease of use?
Reasons to buy
Understand the current clinical landscape by considering the treatment options available for each patient segment.
Visually compare the currently approved treatments available at each line of therapy, based on the most important efficacy and safety parameters tested in clinical trials.
Assess the current late-stage pipeline, in terms of the likely positioning of each product and the implications for the clinical landscape at each line of therapy.
Build up a nuanced understanding of the clinical benchmarks set by these products, and consider how the current late-stage pipeline will affect these benchmarks.
Assess your own pipeline programs in light of these benchmarks, in order to optimally position them and maximize uptake by clinicians.
Themen in dieser Pressemitteilung:
type-2-diabetes-research-report
type-2-diabetes-market-analysis
type-2-diabetes-industry-report
heat-map-and-analysis-research
Unternehmensinformation / Kurzprofil:
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
90 State Street,
Albany, NY 12207,
United States
Toll Free: 866-997-4948 (US-Canada)
Tel: +1-518-621-2074
Email: press(at)marketresearchhub.com
Website: http://www.marketresearchhub.com/
Datum: 16.01.2017 - 08:14 Uhr
Sprache: Deutsch
News-ID 517653
Anzahl Zeichen: 4516
contact information:
Contact person: Mark Hub
Town:
Albany
Phone: 5186212074
Kategorie:
Healthcare & Medical
Typ of Press Release: bitte
type of sending: Veröffentlichung
Date of sending: 16.01.2017
Diese Pressemitteilung wurde bisher 371 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Overview of Type 2 Diabetes Mellitus - Heat Map and Analysis"
steht unter der journalistisch-redaktionellen Verantwortung von
Market Research HUB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
